Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) Sellers Covered 9.65% of Their Shorts

May 24, 2018 - By Peter Erickson

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Logo

The stock of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) registered a decrease of 9.65% in short interest. DFFN’s total short interest was 862,300 shares in May as published by FINRA. Its down 9.65% from 954,400 shares, reported previously. With 86,100 shares average volume, it will take short sellers 10 days to cover their DFFN’s short positions. The short interest to Diffusion Pharmaceuticals Inc’s float is 7.88%.

The stock decreased 0.04% or $0.00019 during the last trading session, reaching $0.51001. About 30,666 shares traded. Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has declined 78.47% since May 24, 2017 and is downtrending. It has underperformed by 90.02% the S&P500.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. The company has market cap of $25.77 million. The Company’s lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme ; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. It currently has negative earnings. The firm is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM.

Another recent and important Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) news was published by Nasdaq.com which published an article titled: “Diffusion Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update” on May 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.